Kansas University has announced a new director of a center designed to take drug discoveries to the marketplace.
Michael Baltezor will serve as the new director of KU’s Biotechnology Optimization Center, a research and commercialization group operating at the Lawrence and KU Medical Center campuses.
The center helps support KU’s effort to obtain National Cancer Institute designation.
Baltezor has worked for drug-related companies since 1976, including 10 years with the Dorsey Laboratories Division of Sandoz, seven years with Quintiles Inc. and 12 years with Marion Laboratories and its successor companies. Most recently he had been serving as vice president of research and development in the Infection Prevention Division of CareFusion Inc.
Baltezor received a doctorate in pharmaceutics and pharmaceutical chemistry in 1977 and a master’s in 1975, both from KU.